与此同时,美国癌症学会估计2024年美国将有大约66440人将被诊断为...查看全文
美股滚雪球2023-09-12 10:16
sell on news,$BioLineRx(BLRX)$ 宣布FDA批准其用于多发性骨髓瘤患者的主要资产Aphexda (motixafortide),这标志着该公司首次获得监管批准,股价不涨反跌。
$百济神州-U(SH688235)$ $君实生物-U(SH688180)$查看全文
产业链观察2023-09-11 20:22
#药闻简讯# $BioLineRx(BLRX)$ 宣布FDA批准APHEXDA与Filgrastim(G-CSF)联用,用于动员多发性骨髓瘤患者的造血干细胞进行采集和随后的自体移植查看全文
美股律师郝俊波2023-01-06 10:39
$BioLineRx(BLRX)$ 【BioLineRx(BLRX)最新证券集体诉讼】
BioLineRx Ltd(NASDAQ: BLRX)因证券欺诈案已经被投资者集体诉讼至法院。在目前的诉讼中投资者指控该公司及部分高管在本案诉讼期间进行虚假陈述,违反证券法令投资者受损。投资者向法院申请判令被告赔偿因其违法行为导致股价下跌给投资...查看全文
BioLineRx(BLRX)2023-01-04 20:12
$BioLineRx(BLRX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-23-000033 Act: 34 Size: 39 KB 网页链接查看全文
BioLineRx(BLRX)04-17 19:15
$BioLineRx(BLRX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-24-001347 Act: 34 Size: 612 KB 网页链接查看全文
BioLineRx(BLRX)04-10 19:35
$BioLineRx(BLRX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-24-001285 Act: 34 Size: 595 KB 网页链接查看全文
BioLineRx(BLRX)04-01 22:45
$BioLineRx(BLRX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-24-001174 Act: 34 Size: 1 MB 网页链接查看全文
BioLineRx(BLRX)04-01 22:35
$BioLineRx(BLRX)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001178913-24-001173 Act: 33 Size: 733 KB 网页链接查看全文
BioLineRx(BLRX)03-27 05:05
$BioLineRx(BLRX)$ 20-F/A [Amend] Annual and transition report of foreign private issuers [Sections 13 or 15(d)] Accession Number: 0001178913-24-001095 Act: 34 Size: 14 MB 网页链接查看全文
里程碑milestone2023-09-03 17:35
07/09/2023 ET
PREVYMIS (Letermovir) $默沙东(MRK)$ $109.84
PDUFA date is expected on September 7, 2023.
网页链接{U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for Merck’s PREVYMIS™ f...查看全文
里程碑milestone2023-09-03 16:58
$BioLineRx(BLRX)$ PDUFA target action date set for September 9, 2023. NDA accepted, noted November 10, 莫替福肽用于多发性骨髓瘤 (MM) 自体移植的干细胞动员 (SCM) Motixafortide in Stem Cell Mobilization (SCM) for Autologous Transplantation in Multiple Myeloma (MM)。 网页链接查看全文
美股律师郝俊波2023-01-06 10:39
$BioLineRx(BLRX)$ 【BioLineRx(BLRX)最新证券集体诉讼】
BioLineRx Ltd(NASDAQ: BLRX)因证券欺诈案已经被投资者集体诉讼至法院。在目前的诉讼中投资者指控该公司及部分高管在本案诉讼期间进行虚假陈述,违反证券法令投资者受损。投资者向法院申请判令被告赔偿因其违法行为导致股价下跌给投资...查看全文
肽研社2022-11-17 11:24
业绩表现
Tonix 2022Q3尚未产生营收,处于亏损状态,净亏损$28.98Mn,研发投入为$22.20Mn。目前,Tonix的鼻内催产素TNX-1900正在开发中,计划于2022Q4启动Ⅱ期临床。
Sesen Bio 2022Q3尚未产生营收,处于亏损状态,净亏损$31.96Mn,研发投入为$29.94Mn。同时,其将与专注开发CAR-M疗法的Ca...查看全文
SeekingBiotech2022-11-10 23:21
BioLineRx (BLRX) Announces FDA Acceptance of NDA for APHEXDA$BioLineRx(BLRX)$查看全文
药研网2022-06-29 11:29
6月28日,以色列一家专注肿瘤学的晚期临床阶段生物制药公司BioLineRx Ltd.宣布,已与劲方医药达成合作协议,通过随机的2b期临床试验推进Motixafortide在胰腺导管腺癌(PDAC)方面的发展。
根据协议条款,劲方医药将全面资助、设计和执行一项随机的2b期临床试验,该试验将在中国招募约200名一线...查看全文
$BioLineRx(BLRX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-22-001132 Act: 34 Size: 415 KB 网页链接
$BioLineRx(BLRX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-22-000899 Act: 34 Size: 45 KB 网页链接
$BioLineRx(BLRX)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001213900-22-006668 Act: 34 Size: 52 KB 网页链接
$BioLineRx(BLRX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-22-000197 Act: 34 Size: 40 KB 网页链接
$BioLineRx(BLRX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-22-000147 Act: 34 Size: 36 KB 网页链接
$BioLineRx(BLRX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-21-003882 Act: 34 Size: 39 KB 网页链接
$BioLineRx(BLRX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-21-003868 Act: 34 Size: 44 KB 网页链接
$BioLineRx(BLRX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-21-003777 Act: 34 Size: 12 KB 网页链接
$BioLineRx(BLRX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-21-003640 Act: 34 Size: 970 KB 网页链接
$BioLineRx(BLRX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-21-003387 Act: 34 Size: 173 KB 网页链接